Journal: bioRxiv
Article Title: Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function
doi: 10.1101/2024.07.12.603279
Figure Lengend Snippet: A, Diagram of domain architecture of EGFR, showing heterodimerization between EGFR and a binding partner such as Her2. Yellow star indicates approximate site of the common oncogenic L858 mutation, red star indicates approximate site of the N361 glycosylation site, green indicates ligands such as EGF or AREG that bind to EGFR to induce dimerization. B, Percentage of fluorescent cells from flow cytometry of MCF10A cells that were labeled with anti-EGFR antibody conjugated to Alexa-Fluor 488, or empty puro-IRES-eGFP vector as the stably fluorescent positive control which is not labeled by fluorescent antibody. Cells used were parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A. C, Representative immunofluorescent microscopy images of parental MCF10A cells or MCF10A cells overexpressing cDNAs of EGFR wild-type (WT) or EGFR N361A, stained for EGFR, vimentin, ATP1A1, or DAPI.
Article Snippet: Introduction of N361A by site-directed mutagenesis on the pBABE puro EGFR wild-type (EGFR WT, RRID:Addgene_11011) and pBABE puro EGFR L858R (RRID:Addgene_11012) plasmids was performed by Azenta. pBABE puro IRES-eGFP (RRID:Addgene_14430).
Techniques: Binding Assay, Mutagenesis, Glycoproteomics, Flow Cytometry, Labeling, Plasmid Preparation, Stable Transfection, Positive Control, Microscopy, Staining